ClinicalTrials.gg
CompletedNCT00306189Updated Jun 20, 2013Results posted

A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects

A Phase 2 interventional study of 100 mg AMG 162 and 60 mg AMG 162 in Osteoporosis, sponsored by Amgen. Completed. Open to female participants aged Up to 80 Years. Per ClinicalTrials.gov, last updated 2013-06-20.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
212
Allocation
Randomized
Ages
Up to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.

Enrollment
20th of 64
212 · median 90
Started
2006
with 4 others
Phase 2
14 of 64
1 open now
Registered
5th of 64
by date
Lead sponsor
22 of 64
Amgen

Among the 64 studies testing denosumab in Osteoporosis, this one is the 20th largest by enrollment, is one of 5 that started in 2006, is one of 14 in phase 2, and was the 5th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: Up to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing denosumab in Osteoporosis, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the effect of AMG 162 (denosumab) treatment on the lumbar spine BMD at month 12 and safety profile across the dose range tested (14, 60 and 100 mg SC once every 6 months) in Japanese postmenopausal osteoporotic subjects compared with those treated with placebo over 12 months.

03

Conditions studied

  • Osteoporosis

Browse trials for

Keywords

  • RANKL
  • RANK
  • denosumab
  • AMG 162
  • osteoporosis
  • bone turnover
  • bone mineral density
  • Japanese
04

Who can participate

Ages eligible
Up to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: - Ambulatory women. - BMD values (g/cm2, Hologic) must be lower than 0.714 at lumbar spine, 0.515 at femoral neck, 0.588 at total hip. - BMD values must not be lower than 0.535 at the lumbar spine, 0.406 at the femoral neck and 0.478 at the total hip. Exclusion Criteria: - Oral bisphosphonate treatments, PTH or PTH derivatives use within the last 12 months and administration of any of anti-osteoporotic treatments within the last 3 months before initial administration of the product. - History of hypocalcemia. - More than two moderate vertebral fractures or any severe vertebral fracture.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
212 participants (actual)

Study arms

  • Active comparator
    100 mg AMG 162

    Drug: 100 mg AMG 162

  • Active comparator
    60 mg AMG 162

    Drug: 60 mg AMG 162

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Active comparator
    14 mg AMG 162

    Drug: 14 mg AMG 162

Interventions

  • 100 mg AMG 162 (denosumab) SC every 6 months

  • 60 mg AMG 162 (denosumab) SC every 6 months

  • 14 mg AMG 162 (denosumab) SC every 6 months

  • DrugPlacebo

    Placebo SC every 6 months

06

What researchers measure

Primary outcomes

  1. Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

    Time frame: 12 months

07

Results

Posted Jan 27, 2010

Participant flow

Participant flow — Overall Study
MilestoneDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MPlacebo
Started57565657
Completed48504552
Not completed96115
Withdrew: Physician decision0001
Withdrew: Adverse event3322
Withdrew: Withdrawal by subject4281
Withdrew: Ineligibility determined1111
Withdrew: Other1000

Outcome measures

PrimaryLumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

Time frame:
12 months
Reported as:
Mean · Percent Change from Baseline
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12
Percent Change from BaselinePlaceboDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6M
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12.46 (-.23 to 1.15)5.71 (4.76 to 6.65)6.73 (5.71 to 7.75)7.45 (6.38 to 8.53)
Statistical analysis
  • Placebo vs Denosumab 100 mg Q6M · t-test, 2 sided · p = <0.0001 · Mean difference (final values): 7 · 95% CI 5.76 to 8.24
  • Placebo vs Denosumab 14 mg Q6M · t-test, 2 sided · p = <0.0001 · Mean difference (final values): 5.25 · 95% CI 4.1 to 6.4
  • Placebo vs Denosumab 60 mg Q6M · t-test, 2 sided · p = <0.0001 · Mean difference (final values): 6.27 · 95% CI 5.06 to 7.49

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—4/54 (7.4%)49/54 (90.7%)
Denosumab 14 mg Q6M—6/53 (11.3%)50/53 (94.3%)
Denosumab 60 mg Q6M—4/54 (7.4%)47/54 (87%)
Denosumab 100 mg Q6M—2/51 (3.9%)48/51 (94.1%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventPlaceboDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6M
HaemorrhoidsGastrointestinal disorders0/540/530/541/51
Cerebral artery embolismNervous system disorders0/540/530/541/51
Meniere's diseaseEar and labyrinth disorders0/541/530/540/51
Colitis ischaemicGastrointestinal disorders0/541/530/540/51
Colonic polypGastrointestinal disorders0/541/530/540/51
Intestinal ischaemiaGastrointestinal disorders0/541/530/540/51
Subdural haematomaInjury, poisoning and procedural complications0/541/530/540/51
Varicose veinVascular disorders0/541/530/540/51
PalpitationsCardiac disorders0/540/531/540/51
ColitisGastrointestinal disorders1/540/530/540/51
Most frequent other events
Showing 10 of 36
Most frequent other events
EventPlaceboDenosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6M
NasopharyngitisInfections and infestations21/5418/5322/5422/51
Back painMusculoskeletal and connective tissue disorders4/543/538/549/51
ContusionInjury, poisoning and procedural complications8/541/534/541/51
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders8/544/533/546/51
HeadacheNervous system disorders5/547/536/543/51
EczemaSkin and subcutaneous tissue disorders5/546/534/546/51
PeriarthritisMusculoskeletal and connective tissue disorders6/541/531/541/51
Joint sprainInjury, poisoning and procedural complications2/541/531/545/51
HypoaesthesiaNervous system disorders3/541/532/545/51
ConstipationGastrointestinal disorders1/545/535/542/51

Baseline characteristics

Age Continuous
Age Continuous(Years)Denosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MPlaceboTotal
Mean65.9 ± 7.165.1 ± 6.364.6 ± 7.164.6 ± 765.1 ± 6.8
Sex: Female, Male
Sex: Female, Male(Participants)Denosumab 14 mg Q6MDenosumab 60 mg Q6MDenosumab 100 mg Q6MPlaceboTotal
Female53545055212
Male00000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Nakamura T, Matsumoto T, Sugimoto T, Shiraki M. Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis. Osteoporos Int. 2012 Mar;23(3):1131-40. doi: 10.1007/s00198-011-1786-8. Epub 2011 Sep 17. PubMed 21927920 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006, a primary completion of Jun 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 2 years 7 months after primary completion. A results delay was requested in Nov 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2006
First posted
Mar 23, 2006
Start
Jan 2006
Primary completionActual
Jun 2007
CompletionActual
Nov 2007
Results delay requested
Nov 23, 2009
Results first posted
Jan 27, 2010
Last update
Jun 20, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00306189
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Mar 23, 2006
Start date
Jan 2006
Primary completion
Jun 2007
Completion
Nov 2007
Results posted
Jan 27, 2010
Last update
Jun 20, 2013

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion